Table 3.
Relationship between types of residual tumor and expression of ERa, PRa and HER2b
|
Types |
No. of ER (%) prior to NCT |
No. of ER (%) after NCT |
||||||
|---|---|---|---|---|---|---|---|---|
| - | + to about +++ | χ2 | P value | - | + to about +++ | χ2 | P value | |
| Type I |
21 (38.2) |
34 (61.8) |
2.032 |
0.362 |
22 (40.0) |
33 (60.0) |
0.378 |
0.828 |
| Type II |
7 (23.3) |
23 (76.7) |
10 (33.3) |
20 (66.7) |
||||
| Type III |
2 (40.0) |
3 (60.0) |
2 (40.0) |
3 (60.0) |
||||
| |
No. of PR (%) prior to NCT |
No. of PR (%) after NCT |
||||||
| |
- |
+ to about +++ |
χ2 |
P value |
- |
+ to about +++ |
χ2 |
P value |
| Type I |
13 (23.6) |
42 (76.4) |
0.499 |
0.779 |
13 (23.6) |
42 (76.4) |
0.153 |
0.926 |
| Type II |
9 (30.0) |
21 (70.0) |
8 (26.7) |
22 (73.3) |
||||
| Type III |
1 (20.0) |
4 (80.0) |
1 (20.0) |
4 (80.0) |
||||
| |
No. of HER2 (%) before NCT |
No. of HER2 (%) after NCT |
||||||
| |
– to about + |
++ to about ++++ |
χ2 |
P value |
– to about + |
++ to about +++ |
χ2 |
P value |
| Type I |
32 (58.2) |
23 (41.8) |
0.743 | 0.154 | 39 (70.9) |
16 (29.1) |
1.142 | 0.565 |
| Type II |
24 (80.0) |
6 (20.0) |
24 (80.0) |
6 (20.0) |
||||
| Type III | 4 (80.0) | 1 (20.0) | 4 (80.0) | 1 (20.0) | ||||
aχ2 test. bKruskal-Wallis test.